- SYNB1020 Oral Treatment Resulted in a Significant Dose-Dependent Effect on a Plasma Nitrogen Endpoint Demonstrating Mechanistic Activity - - Data Support Initiation of Two Phase 1b/2a Studies in 2018 - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 8, 2017-- Synlogic, Inc .,( Nasdaq:SYBX ) a...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 24, 2017-- Synlogic ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to probiotics to develop novel living medicines, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Orphan Drug Designation to SYNB1618,...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 10, 2017-- Synlogic ( Nasdaq: SYBX ) announced the addition of two experienced executives to key leadership roles: Andrew Gengos as Chief Operating Officer and Head of Corporate Development, and Adam Thomas as Chief Human Resources Officer....

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 20, 2017-- Synlogic (Nasdaq: SYBX) announced today that JC Gutiérrez-Ramos, Synlogic’s president and chief executive officer, will present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology at 4:00 p.m....

Data support the lead clinical program in urea cycle disorders (UCD) and the further development of Synthetic Biotic™ candidates as potential treatments for phenylketonuria (PKU) and maple syrup urine disease (MSUD) CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep....

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 1, 2017-- Synlogic (Nasdaq:SYBX) announced today that its chief medical officer, Aoife Brennan , M.B., B.Ch., will present a company overview at BioCentury’s 24 th Annual NewsMakers in the Biotech Industry Conference on Friday, September 8, 2017 , at 10:00...

- Synlogic Commences Trading on NASDAQ Capital Market under Ticker Symbol “SYBX” - Combined Company has Approximately $100 Million in Cash and Cash Equivalents Following Transaction Close - Company Strengthens Board of Directors with addition of Michael Powell , Ph.D., and Richard Shea CAMBRIDGE,...

– Novel Synthetic Biotic™ medicine, SYNB1020, under development for the treatment of hyperammonemia due to urea cycle disorders – CAMBRIDGE, Mass–( BUSINESS WIRE )–Synlogic™ has been granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its lead product candidate,...

Healthy volunteers study initiated for SYNB1020, a Synthetic Biotic™ medicine for the treatment of hyperammonemia                                                    ...

–   Discoveries support next phase of collaboration with AbbVie –     Cambridge, Mass (Business Wire)  – Synlogic™ has completed the first phase of its ongoing collaboration with AbbVie. During this first discovery phase of the collaboration Synlogic has identified Synthetic...

CAMBRIDGE, Mass. –( BUSINESS WIRE )–Synlogic announced today that its President and Chief Executive Officer, Jose Carlos Gutierrez-Ramos, Ph.D., will speak at the Jefferies 2017 Global Healthcare Conference on Friday, June 9th at 1:30 p.m. in New York City....

On May 16, 2017, Synlogic and Mirna Therapeutics held a conference call to discuss the proposed merger as well as Synlogic’s platform and pipeline assets. The replay can be accessed through the below link and conference ID. Webcast Link:  http://edge.media-server.com/m/p/zutpri3c Conference ID...